Name: Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay (Video) | JoVE Journal
Uploaded: 2024-09-27T14:55:00.000+00:00
Duration: 7 min 5 s
Description: Learn to measure deubiquitylating enzyme activity for neurodevelopmental disorder research using recombinant protein purification and ubiquitin chain cleavage assays. This substrate-independent method directly assesses genetic variant impacts.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work was funded by Sanford Research startup funds to FB and the NIH grant R01CA233700 to MJS. The artwork was done by Felipe G. Serrano (www.illustrative-science.com).&#160;We thank Dr. Greg Findlay (University of&#160;Dundee) for the GST-USP27X plasmid.

The following protocol can be adapted for recombinant proteins using various affinity tags expressed in different strains of competent cells. Depending on the protein being expressed, the culturing and overnight expression conditions may require optimization of the OD600 at expression induction, expression time, expression temperature, and IPTG concentration. An overview of the protocol is illustrated in Figure 1. The details of the reagents and the equipment used in this study are listed in the Table of Materials.
1. Transformation of competent Rosetta 2 E. coli cells with the recombinant GST-USP27X expression plasmid
NOTE: To maintain the sterility of the bacterial culture, perform steps where media containers are open under a Bunsen burner flame. To allow optimal oxygen transfer, perform bacterial culture shaking in a benchtop temperature-controlled shaker with an orbit of 19 mm to 50 mm and a speed of 200 rpm29.
<ol>
	<li>Thaw 20 µL of chemically competent Rosetta 2 E. coli cells on ice immediately before use. Add 1-10 ng of the pGEX6P1-USP27X expression plasmid (encoding for N-terminal Glutathione-S-transferase (GST)30 -tagged USP27X and containing Ampicillin resistance) and incubate 5 min on ice.</li>
	<li>Heat shock for 30 s at 42 °C in a dry bath. Incubate on ice for 2 min.</li>
	<li>Add 80 µL of room temperature (RT) SOC medium. Incubate for 60 min at 37 °C with 200 rpm rotation in a 19 mm orbit benchtop temperature-controlled shaker.</li>
	<li>Plate 50 µL of culture on an LB agar plate supplemented with 25 µg/L Chloramphenicol and 50 µg/L Ampicillin. Incubate for 20 h at 37 °C lid-side down in a temperature-controlled incubator.</li>
</ol>
2. Overnight bacterial expression of recombinant protein from expression plasmid
NOTES: To maintain the sterility of the bacterial culture, perform steps where media containers are open under a Bunsen burner flame. To allow optimal oxygen transfer, perform bacterial culture shaking in a benchtop temperature-controlled shaker with an orbit of 19 mm to 50 mm and a speed of 200 rpm29. Measure culture OD600 using a spectrophotometer.
<ol>
	<li>Prepare 1 L of Terrific Broth (TB) medium by adding 47.6 g of TB Powder to 1 L of ultrapure water with 0.4% glycerol in a 2 L baffled culture flask. Autoclave medium for 30 min and cool to RT.</li>
	<li>Pick a single colony of transformed bacteria and add to 10 mL of sterile LB medium supplemented with 25 µg/L Chloramphenicol and 50 µg/L Ampicillin. Incubate for 20 h at 37 °C with 200 rpm rotation in a 19 mm orbit benchtop temperature-controlled shaker.</li>
	<li>Add 10 mL overnight culture to 1 L of TB medium supplemented with 25 µg/L Chloramphenicol and 50 µg/L Ampicillin (1:100 ratio of starting culture to expression culture). Incubate at 37 °C with 200 rpm rotation in a 19 mm orbit benchtop temperature-controlled shaker until the culture OD600 is between 0.5-0.6.</li>
	<li>Add 50 µM of IPTG to the culture to induce expression, cool to 16 °C, and incubate for 20 h at 16 °C with 200 rpm rotation.</li>
	<li>Pellet cells from expression culture by centrifugation for 20 min at ≥3,000 x g and 4 °C. Store the pellet at -80 °C for at least 1 h. 
	NOTE: At this point, the experiment can be paused and restarted later (preferably the same week). The pellet can be stored for the long term at -80 °C.</li>
</ol>
3. Protein purification by gravity-flow affinity column
NOTE: The resin, binding, wash, elution, and storage buffers appropriate for each purification will depend on the recombinant protein being purified. Collect samples from the cell pellet, supernatant, flow-through, wash fractions, and elution fractions in SDS-PAGE buffer. Perform SDS-PAGE and Coomassie staining for the samples to evaluate the success of the purification. Perform purification at 4 °C and handle fractions on ice. Cleavage of protein tags can be performed on or off the column using the appropriate protease to target the relevant protease-specific cleavage site.
<ol>
	<li>Secure the empty gravity flow column in the retort stand and fill it with glutathione agarose resin. Use 2-3 mL of resin to purify a cell pellet collected from 1 L of expression culture.</li>
	<li>Wash the column with one resin-bed volume of 20% ethanol. Wash column 3 times with one resin-bed volume of MS500 buffer (20 mM of Tris pH 7.5, 500 mM of NaCl, 0.5 mM of TCEP). Stop the column so the resin remains covered with buffer to prevent drying while preparing the cell pellet.</li>
	<li>Thaw the cell pellet at 4 °C. Add 30 mL of MS500 buffer (20 mM of Tris pH 7.5, 500 mM of NaCl, 0.5 mM of TCEP, 60 mg of lysozyme, and one protease inhibitor tablet) to the thawed pellet. Lyse for 30 min at 4 °C with gentle end-over-end rotation.</li>
	<li>Sonicate lysed cells in either a 50 mL centrifuge tube or a metal beaker on ice until the lysate flows freely when dispensed from a pipette tip. Centrifuge for 30 min at 4 °C and ≥20,000 x g to clear the supernatant. 
	NOTE: Determine sonicator settings empirically. Set the sonicator such that 120 s total time is enough to reduce the viscous lysate to a free-flowing and transparent liquid.</li>
	<li>Decant the supernatant into a beaker and load cleared lysate onto the column. Run lysate through the column by gravity flow while collecting the flow through. Load the column with the collected flow through and run it through the column.</li>
	<li>Wash the column with at least two resin-bed volumes of MS500 wash buffer (20 mM of Tris pH 7.5, 500 mM of NaCl, 0.5 mM of TCEP) 5 times. Collect the wash flow through in 5 mL fractions. Add 1 µL of each fraction to 100 µL of Bradford reagent to visually check for protein presence. Wash until unbound protein is no longer present in the last wash, adding additional wash steps if necessary.</li>
	<li>Recover protein by running MS500 elution buffer (MS500 buffer supplemented with 10 mM of glutathione and 10 mM of NaOH) through the column, collecting 5 mL elution fractions. Check for protein presence by adding 1 µL of eluate to 100 µL of Bradford reagent. Stop collecting fractions when the Bradford reagent no longer indicates proteins are present.</li>
	<li>Perform buffer exchange by precipitation and centrifugation. Precipitate protein by adding 2 volumes of 4 M of ammonium sulfate to the eluate, gently inverting until cloudy, and then centrifuging for 30 min at 4 °C and ≥20,000 x g and again for another 5 min. Remove the supernatant after each centrifugation without disturbing the protein pellet.</li>
	<li>Re-dissolve and store protein in MS500 supplemented with 25% glycerol. Store protein pellets or protein in storage buffer at -80 °C.</li>
</ol>
4. In vitro ubiquitin chain cleavage assay
NOTE: Select ubiquitin chain length and linkage types based on DUB specificity described in previous reports31 or determined empirically. If necessary, this protocol could be used to test the activity of the wild-type DUB of interest on a panel of commercially available ubiquitin chains of defined length and linkage type. A di-ubiquitin chain amount of 375-750 ng and a DUB concentration of 1-2 µM can be used as starting points for the assay27.
<ol>
	<li>Prepare 10x DUB activation buffer (500 mM of Tris-HCl pH 7.5, 500 mM of NaCl, and 100 mM of TCEP).</li>
	<li>For each time point for each DUB, prepare 10 µL total of 2 µM of purified GST-USP27X in 1x DUB activation buffer (DUB mix). Prepare master mixes and split them into time points.</li>
	<li>Incubate the DUB mix for 10 min at RT.</li>
	<li>Add 7 µL of SDS-PAGE loading buffer to time 0 before adding ubiquitin chains to prevent the deubiquitylation reaction from starting.</li>
	<li>To each time point for each DUB, add 375 ng of K-63 di-ubiquitin chains diluted in 10 µL 1x DUB activation buffer. The total volume is 20 µL per reaction.</li>
	<li>Incubate the tubes at 30 °C, stopping each time point with 7 µL of SDS-PAGE loading buffer.</li>
	<li>Perform SDS-PAGE with a 4%-12% gradient gel and immunoblot7,32 for ubiquitin and USP27X to analyze the change in mono-ubiquitin presence across selected time points.</li>
</ol>
<img alt="Protein purification process diagram: transformation, expression, lysis, affinity, SDS-PAGE analysis." class="xfigimg" src="/files/ftp_upload/67367/67367fig01v2.jpg" data-altupdatedat="1788304762000" data-alt="Figure 1"> 
Figure 1: Schematic of the study design. (A) Transformation of competent E. coli cells with recombinant protein expression plasmid. (B) Overnight bacterial expression of recombinant deubiquitylase protein. (C) Protein purification of recombinant deubiquitylase using a gravity-flow affinity column. (D) In vitro ubiquitin chain cleavage assay to evaluate deubiquitylating activity. <a href="https://www.jove.com/files/ftp_upload/67367/67367fig01largev2.jpg" target="_blank">Please click here to view a larger version of this figure.</a>

Assessing DUB Variants in Neurodevelopmental Disorders Using a Cleavage Assay

<ol><li>Morris-Rosendahl, D. J., Crocq, M. -A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Neurodevelopmental+disorders%3A+the+history+and+future+of+a+diagnostic+concept%5BTitle%5D)+AND+%22Dialogues+Clin+Neurosci%22%5BJournal%5D)">Neurodevelopmental disorders: the history and future of a diagnostic concept.</a> Dialogues Clin Neurosci. 22 (1), 65-72 (2020).</li>
<li>Ebstein, F., Küry, S., Papendorf, J. J., Krüger, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Neurodevelopmental+disorders+%28NDD%29+caused+by+genomic+alterations+of+the+ubiquitin-proteasome+system+%28UPS%29%3A+the+possible+contribution+of+immune+dysregulation+to+disease+pathogenesis%5BTitle%5D)+AND+%22Front+Mol+Neurosci%22%5BJournal%5D)">Neurodevelopmental disorders (NDD) caused by genomic alterations of the ubiquitin-proteasome system (UPS): the possible contribution of immune dysregulation to disease pathogenesis.</a> Front Mol Neurosci. 14, 733012(2021).</li>
<li>Hershko, A., Ciechanover, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+ubiquitin+system%5BTitle%5D)+AND+%22Annu+Rev+Biochem%22%5BJournal%5D)">The ubiquitin system.</a> Annu Rev Biochem. 67 (10), 425-479 (1998).</li>
<li>Pickart, C. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mechanisms+underlying+ubiquitination%5BTitle%5D)+AND+%22Annu+Rev+Biochem%22%5BJournal%5D)">Mechanisms underlying ubiquitination.</a> Annu Rev Biochem. 70 (1), 503-533 (2001).</li>
<li>Komander, D., Clague, M. J., Urbé, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Breaking+the+chains%3A+structure+and+function+of+the+deubiquitinases%5BTitle%5D)+AND+%22Nat+Rev+Mol+Cell+Biol%22%5BJournal%5D)">Breaking the chains: structure and function of the deubiquitinases.</a> Nat Rev Mol Cell Biol. 10 (8), 550-563 (2009).</li>
<li>Yau, R., Rape, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+increasing+complexity+of+the+ubiquitin+code%5BTitle%5D)+AND+%22Nat+Cell+Biol%22%5BJournal%5D)">The increasing complexity of the ubiquitin code.</a> Nat Cell Biol. 18 (6), 579-586 (2016).</li>
<li>Koch, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((USP27X+variants+underlying+X-linked+intellectual+disability+disrupt+protein+function+via+distinct+mechanisms%5BTitle%5D)+AND+%22Life+Sci+Alliance%22%5BJournal%5D)">USP27X variants underlying X-linked intellectual disability disrupt protein function via distinct mechanisms.</a> Life Sci Alliance. 7 (3), e202302258(2024).</li>
<li>Hao, Y. -H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((USP7+acts+as+a+molecular+rheostat+to+promote+WASH-dependent+endosomal+protein+recycling+and+is+mutated+in+a+human+neurodevelopmental+disorder%5BTitle%5D)+AND+%22Mol+Cell%22%5BJournal%5D)">USP7 acts as a molecular rheostat to promote WASH-dependent endosomal protein recycling and is mutated in a human neurodevelopmental disorder.</a> Mol Cell. 59 (6), 956-969 (2015).</li>
<li>Fountain, M. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Pathogenic+variants+in+USP7+cause+a+neurodevelopmental+disorder+with+speech+delays%2C+altered+behavior%2C+and+neurologic+anomalies%5BTitle%5D)+AND+%22Genet+Med%22%5BJournal%5D)">Pathogenic variants in USP7 cause a neurodevelopmental disorder with speech delays, altered behavior, and neurologic anomalies.</a> Genet Med. 21 (8), 1797-1807 (2019).</li>
<li>Santiago-Sim, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Biallelic+variants+in+OTUD6B+cause+an+intellectual+disability+syndrome+associated+with+seizures+and+dysmorphic+features%5BTitle%5D)+AND+%22Am+J+Hum+Genet%22%5BJournal%5D)">Biallelic variants in OTUD6B cause an intellectual disability syndrome associated with seizures and dysmorphic features.</a> Am J Hum Genet. 100 (4), 676-688 (2017).</li>
<li>Beck, D. B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Linkage-specific+deubiquitylation+by+OTUD5+defines+an+embryonic+pathway+intolerant+to+genomic+variation%5BTitle%5D)+AND+%22Sci+Adv%22%5BJournal%5D)">Linkage-specific deubiquitylation by OTUD5 defines an embryonic pathway intolerant to genomic variation.</a> Sci Adv. 7 (4), eabe2116(2021).</li>
<li>Cho, J., Park, J., Kim, E. E., Song, E. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Assay+systems+for+profiling+deubiquitinating+activity%5BTitle%5D)+AND+%22Int+J+Mol+Sci%22%5BJournal%5D)">Assay systems for profiling deubiquitinating activity.</a> Int J Mol Sci. 21 (16), 1-16 (2020).</li>
<li>Matsui, S., Sandberg, A. A., Negoro, S., Seon, B. K., Goldstein, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Isopeptidase%3A+A+novel+eukaryotic+enzyme+that+cleaves+isopeptide+bonds%5BTitle%5D)+AND+%22Proc+Natl+Acad+Sci+USA%22%5BJournal%5D)">Isopeptidase: A novel eukaryotic enzyme that cleaves isopeptide bonds.</a> Proc Natl Acad Sci USA. 79 (5), 1535-1539 (1982).</li>
<li>Rose, I. A., Warms, J. V. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+enzyme+with+ubiquitin+carboxy-terminal+esterase+activity+from+reticulocytes%5BTitle%5D)+AND+%22Biochemistry%22%5BJournal%5D)">An enzyme with ubiquitin carboxy-terminal esterase activity from reticulocytes.</a> Biochemistry. 22 (18), 4234-4237 (1983).</li>
<li>Wilkinson, K. D., Cox, M. J., Mayer, A. N., Frey, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Synthesis+and+characterization+of+ubiquitin+ethyl+ester%2C+a+new+substrate+for+ubiquitin+carboxyl-terminal+hydrolase%5BTitle%5D)+AND+%22Biochemistry%22%5BJournal%5D)">Synthesis and characterization of ubiquitin ethyl ester, a new substrate for ubiquitin carboxyl-terminal hydrolase.</a> Biochemistry. 25 (21), 6644-6649 (1986).</li>
<li>Pickart, C. M., Rose, I. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Ubiquitin+carboxyl-terminal+hydrolase+acts+on+ubiquitin+carboxyl-terminal+amides%5BTitle%5D)+AND+%22J+Biol+Chem%22%5BJournal%5D)">Ubiquitin carboxyl-terminal hydrolase acts on ubiquitin carboxyl-terminal amides.</a> J Biol Chem. 260 (13), 7903-7910 (1985).</li>
<li>Hadari, T., Warms, J. V. B., Rose, I. A., Hershko, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+ubiquitin+C-terminal+isopeptidase+that+acts+on+polyubiquitin+chains%3A+Role+in+protein+degradation%5BTitle%5D)+AND+%22J+Biol+Chem%22%5BJournal%5D)">A ubiquitin C-terminal isopeptidase that acts on polyubiquitin chains: Role in protein degradation.</a> J Biol Chem. 267 (2), 719-727 (1992).</li>
<li>Woo, S. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Multiple+ubiquitin+C-terminal+hydrolases+from+chick+skeletal+muscle%5BTitle%5D)+AND+%22J+Biol+Chem%22%5BJournal%5D)">Multiple ubiquitin C-terminal hydrolases from chick skeletal muscle.</a> J Biol Chem. 270 (32), 18766-18773 (1995).</li>
<li>Woo, S. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Purification+and+characterization+of+a+new+ubiquitin+C-terminal+hydrolase+%28UCH-1%29+with+isopeptidase+activity+from+chick+skeletal+muscle%5BTitle%5D)+AND+%22J+Biochem%22%5BJournal%5D)">Purification and characterization of a new ubiquitin C-terminal hydrolase (UCH-1) with isopeptidase activity from chick skeletal muscle.</a> J Biochem. 121 (4), 684-689 (1997).</li>
<li>Baek, S. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Molecular+cloning+of+a+novel+ubiquitin-specific+protease%2C+UBP41%2C+with+isopeptidase+activity+in+chick+skeletal+muscle%5BTitle%5D)+AND+%22J+Biol+Chem%22%5BJournal%5D)">Molecular cloning of a novel ubiquitin-specific protease, UBP41, with isopeptidase activity in chick skeletal muscle.</a> J Biol Chem. 272 (41), 25560-25565 (1997).</li>
<li>Wilkinson, K. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Metabolism+of+the+polyubiquitin+degradation+signal%3A+Structure%2C+mechanism%2C+and+role+of+isopeptidase+T%5BTitle%5D)+AND+%22Biochemistry%22%5BJournal%5D)">Metabolism of the polyubiquitin degradation signal: Structure, mechanism, and role of isopeptidase T.</a> Biochemistry. 34 (44), 14535-14546 (1995).</li>
<li>Hu, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Crystal+structure+of+a+UBP-family+deubiquitinating+enzyme+in+isolation+and+in+complex+with+ubiquitin+aldehyde%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde.</a> Cell. 111 (7), 1041-1054 (2002).</li>
<li>Hu, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Structure+and+mechanisms+of+the+proteasome-associated+deubiquitinating+enzyme+USP14%5BTitle%5D)+AND+%22EMBO+J%22%5BJournal%5D)">Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14.</a> EMBO J. 24 (21), 3747-3756 (2005).</li>
<li>Gorka, M., Magnussen, H. M., Kulathu, Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Chemical+biology+tools+to+study+deubiquitinases+and+UBL+proteases%5BTitle%5D)+AND+%22Semin+Cell+Dev+Biol%22%5BJournal%5D)">Chemical biology tools to study deubiquitinases and UBL proteases.</a> Semin Cell Dev Biol. 132, 86-96 (2022).</li>
<li>Faesen, A. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+differential+modulation+of+USP+activity+by+internal+regulatory+domains%2C+interactors%2C+and+eight+ubiquitin+chain+types%5BTitle%5D)+AND+%22Chem+Biol%22%5BJournal%5D)">The differential modulation of USP activity by internal regulatory domains, interactors, and eight ubiquitin chain types.</a> Chem Biol. 18 (12), 1550-1561 (2011).</li>
<li>Mevissen, T. E. T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((OTU+deubiquitinases+reveal+mechanisms+of+linkage+specificity+and+enable+ubiquitin+chain+restriction+analysis%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis.</a> Cell. 154 (1), 169-184 (2013).</li>
<li>Kwasna, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Discovery+and+characterization+of+ZUFSP%2FZUP1%2C+a+distinct+deubiquitinase+class+important+for+genome+stability%5BTitle%5D)+AND+%22Mol+Cell%22%5BJournal%5D)">Discovery and characterization of ZUFSP/ZUP1, a distinct deubiquitinase class important for genome stability.</a> Mol Cell. 70 (1), 150-164.e6 (2018).</li>
<li>Hu, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((X-exome+sequencing+of+405+unresolved+families+identifies+seven+novel+intellectual+disability+genes%5BTitle%5D)+AND+%22Mol+Psychiatry%22%5BJournal%5D)">X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes.</a> Mol Psychiatry. 21 (1), 133-148 (2016).</li>
<li>Hartmann, I. Shaker Orbit - Revolving in Space Around the Samples? Eppendorf Lab Academy. Eppendorf Lab Academy. , at 
 <a target="_blank" href="https://www.eppendorf.com/us-en/lab-academy/lab-solutions/others/shaker-orbit-revolving-in-space-around-the-samples">https://www.eppendorf.com/us-en/lab-academy/lab-solutions/others/shaker-orbit-revolving-in-space-around-the-samples</a> (2020).</li>
<li>Smith, D. B., Johnson, K. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Single-step+purification+of+polypeptides+expressed+in+Escherichia+coli+as+fusions+with+glutathione+S-transferase%5BTitle%5D)+AND+%22Gene%22%5BJournal%5D)">Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.</a> Gene. 67 (1), 31-40 (1988).</li>
<li>Ritorto, M. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Screening+of+DUB+activity+and+specificity+by+MALDI-TOF+mass+spectrometry%5BTitle%5D)+AND+%22Nat+Commun%22%5BJournal%5D)">Screening of DUB activity and specificity by MALDI-TOF mass spectrometry.</a> Nat Commun. 5, 4763(2014).</li>
<li>Bustos, F., Bustos, F. Immunoblotting using precast gels. , protocols.io (2024).</li>
<li>Wingfield, P. T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Overview+of+the+purification+of+recombinant+proteins%5BTitle%5D)+AND+%22Curr+Protoc+Protein+Sci%22%5BJournal%5D)">Overview of the purification of recombinant proteins.</a> Curr Protoc Protein Sci. 80, 6.1.1-6.1.35 (2015).</li>
</ol>

The authors declare no conflicts of interest.

This article presents a protocol for the expression and purification of recombinant USP27X DUBs and an in vitro ubiquitin chain cleavage assay to compare the deubiquitylating activity of wild-type USP27X and NDD-associated variant proteins. This assay determined that XLID105-associated variants disrupt USP27X catalytic activity7. This mechanistic insight helped us define XLID105 as a USP27X functional disruption disorder.
This protocol can be adapted to other DUBs that are associated with genetic diseases with poorly understood molecular mechanisms. The optimization of the expression and purification protocol for a specific DUB of interest is crucial. If no specific protocols have been described for a given DUB of interest, the method described here can act as a starting point. When optimizing a protein expression and purification protocol, critical steps include selecting the appropriate parameters for (1) the expression system (e.g., bacteria strains, insect cells, or mammalian cells), (2) the expression vectors, (3) the tag and affinity resin to be used, (4) the growing conditions, (5) the amounts of culture, and (6) the need for further purification (e.g., via size exclusion or ion exchange chromatography). Specific recommendations for these and other aspects of the method have been discussed33.
The in vitro ubiquitin chain cleavage assay is a simple way to measure the deubiquitylating activity of wild-type or mutant DUBs. A time-dependent analysis of ubiquitin cleavage can provide insights into the effects of genetic variation on DUB enzymatic kinetics by allowing the determination of parameters such as the Km and Vmax. This would enable one to distinguish between defects in the DUB active site that impair catalysis (reduced Vmax) and those that impair substrate recognition (increased Km). The versatility of this assay stems from the variety of ubiquitin chains that can be used to provide distinct mechanistic information on a DUB of interest. Ubiquitin chains of different lengths and linkage topologies are commercially available, rendering this assay accessible to non-experts. Specific DUBs have unique properties for enzymatic kinetics, linkage recognition, and cleavage. Critical steps for this assay include (1) defining a working concentration of the DUB, (2) determining the optimal reaction time, (3) choosing the ubiquitin chain linkage type and length, and (4) selecting a detection method.
Ubiquitin chain cleavage assays measure the impact of NDD variants on DUB activity7,11, helping to identify variants that disrupt DUB activity and drive atypical development. This assay can be used in a range of situations where genetic variation drives pathology, including cancer and neurodegeneration. As a substrate-independent assay, prior identification of a specific ubiquitylated protein substrate is not required. However, the assay is limited to measuring changes in ubiquitin chain cleavage activity and cannot assess variants&#39; effects on DUB functions such as protein-protein interactions, subcellular localization, and posttranslational modifications. Identification of the broad signaling pathways where a DUB of interest operates is required to develop specific assays to address how these variants drive discrete NDDs.

Neurodevelopmental disorders (NDDs) arise from diverse etiologies with environmental or genetic determinants that drive atypical nervous system development1. Next-generation sequencing genetic testing has linked an increasing number of variants in ubiquitin system-related genes with genetic NDDs2. The ubiquitin system catalyzes the ligation of the small protein modifier ubiquitin to primarily lysine residues in protein substrates to drive changes in cellular behavior, including localization, stability, protein-protein interactions, or activity3. Ubiquitylation is mediated by E1 activating, E2 conjugating, and E3 ligase enzymes4 and is reversible by the activity of deubiquitylating enzymes (DUBs) that catalyze the cleavage and removal of ubiquitin from protein substrates5. Ubiquitin can be ligated to the substrate as a monomer (monoubiquitylation) or polymeric chains (polyubiquitylation) that are formed on any of the seven lysine residues (K6, K11, K27, K29, K33, K48, K63) or the M1 residue of ubiquitin. These different ubiquitin chain topologies and their combinations create a cellular code that is key for signal transduction6.
DUBs such as USP27X, USP7, USP9X, USP48, STAMBP, OTUD4, OTUD6B, and OTUD5 have been associated with NDDs2,7,8,9,10,11. For most NDDs, the molecular mechanisms that drive pathogenesis remain experimentally undefined. Some of the DUBs driving recently described disorders are poorly understood and lack known cellular readouts that can be used to assess the impact of genetic variation on protein function. In vitro, ubiquitin chain cleavage assays overcome this limitation as substrate-independent DUB activity readouts that can measure the impact of gene variants on enzymatic activity12.
In vitro ubiquitin cleavage assays have been used since the 1980s. These assays using radiolabeled substrates allowed for the discovery of the first DUBs, including isopeptidase, identified for its capacity to deubiquitylate Histone H2A13, and ubiquitin carboxyl-terminal hydrolase (UCH), identified by its ability to hydrolyze ubiquitin from a variety of chemical conjugates14,15,16. Further, radiolabeled polyubiquitylated full-length proteins or peptides were used to identify isopeptidase T and several UCHs and ubiquitin-specific proteases (UBPs) from erythrocytes and skeletal muscle, respectively17,18,19,20. Ubiquitin chains of a defined length and linkage type (K48-linked tetra-ubiquitin) were first used to measure the DUB activity of Isopeptidase T21. Since then, this assay has become the gold standard to measure DUB activity in mutational analyses22,23. The refinement of this assay currently allows visualization of ubiquitin cleavage via electrophoresis and conventional gel stains such as Coomassie blue, SYPRO orange, ruby, and silver stain or fluorescent or immunoblotting-based detection12,24. Molecular aspects of DUB activity, such as minimum chain length and linkage specificity25,26,27,28, can be clarified by using ubiquitin chains of different lengths (e.g., di-, tri-, tetra-ubiquitin) and linkages (K6, K11, K27, K29, K33, K48, K63, linear) in functional assays. NDD-associated variants can drive DUB activity defects that are ubiquitin chain linkage type specific11.
A di-ubiquitin cleavage assay using purified recombinant DUB proteins can directly measure the impact of NDD variants on DUB activity. USP27X, which is mutated in the NDD X-linked intellectual disability disorder 105 (XLID105)7,28 models the process presented here. This approach allows for the determination of how DUB activity is disrupted by gene variants in existing and unknown DUB-associated NDDs.

<table><tbody><tr><td>Amersham Protran 0.45 NC 200 mm &amp;times; 200 mm 25/PK</td><td>Cytiva</td><td>10600041</td><td></td></tr><tr><td>Ammonium sulfate</td><td>Fisher Scientific</td><td>AC205872500</td><td></td></tr><tr><td>Ampicillin</td><td>Fisher Scientific</td><td>BP1760 25</td><td></td></tr><tr><td>Anti- Ubiquitin (Mouse monoclonal)</td><td>Biolegend</td><td>Cat# 646302, RRID:AB_1659269</td><td>(WB: 1:1000)</td></tr><tr><td>Anti-GST (Sheep polyclonal)</td><td>MRC-PPU Reagents and Services</td><td>Cat# S902A Third bleed</td><td>(WB: 1:1000) https://mrcppureagents.dundee.ac.uk/</td></tr><tr><td>Baffled Culture Flasks 2 L</td><td>Fisher Scientific</td><td>10-042-5N</td><td></td></tr><tr><td>Bradford Reagent</td><td>Millipore Sigma</td><td>B6916-500ML</td><td></td></tr><tr><td>Chloramphenicol</td><td>Gold Biotechnology</td><td>C-105-25</td><td></td></tr><tr><td>Complete, Protease Inhibitor tablets</td><td>Millipore Sigma</td><td>5056489001</td><td></td></tr><tr><td>Econo-Column 1.5 &amp;times; 5 cm</td><td>Bio-Rad</td><td>7371507</td><td></td></tr><tr><td>Eppendorf ThermoMixer F1.5&amp;nbsp;</td><td>Eppendorf</td><td>5384000020</td><td></td></tr><tr><td>Excel</td><td>Microsoft</td><td></td><td>https://www.microsoft.com/en-us/microsoft-365/excel</td></tr><tr><td>Glycerol</td><td>Genesee Scientific</td><td>18-205</td><td></td></tr><tr><td>Illustrator</td><td>Adobe</td><td></td><td>https://www.adobe.com/products/illustrator.html</td></tr><tr><td>Image Studio</td><td>LI-COR Biosciences</td><td></td><td>https://www.licor.com/bio/image-studio/</td></tr><tr><td>Inkscape</td><td>Inkscape</td><td></td><td>https://inkscape.org/</td></tr><tr><td>Invitrogen 4-12% NuPAGE 1mm 12 well gel</td><td>Thermo Fisher Scientific</td><td>NP0322BOX</td><td></td></tr><tr><td>IPTG (Isopropyl-b-D-Thiogalactopyranoside)</td><td>Genesee Scientific</td><td>20-109</td><td></td></tr><tr><td>IRDye 800CW Donkey anti-Goat IgG Secondary Antibody</td><td>LI-COR Biosciences</td><td>Cat# 926-32214</td><td>(WB: 1:10000)</td></tr><tr><td>IRDye 800CW Donkey anti-Mouse IgG Secondary Antibody</td><td>LI-COR Biosciences</td><td>Cat# 926-32212</td><td>(WB: 1:10000)</td></tr><tr><td>Isotemp Digital Dry Bath</td><td>Fisher Scientific</td><td>88860022</td><td></td></tr><tr><td>K63 Di-Ubiquitin</td><td>South Bay Bio LLC</td><td>SBB-UP0072</td><td></td></tr><tr><td>LB Agar</td><td>Genesee Scientific</td><td>11-119</td><td></td></tr><tr><td>LB Broth</td><td>Genesee Scientific</td><td>11-118</td><td></td></tr><tr><td>Lysozyme</td><td>Gold Biotechnology</td><td>L-040-100</td><td></td></tr><tr><td>MaxQ 4000 Benchtop Orbital Shaker</td><td>Thermo Fisher Scientific</td><td>SHKE4000-7</td><td></td></tr><tr><td>MES-SDS Running Buffer</td><td>Boston Bioproducts Inc</td><td>BP-177</td><td></td></tr><tr><td>Mini Tube Rotator</td><td>Fisher Scientific</td><td>88-861-051</td><td></td></tr><tr><td>NuPage LDS Sample buffer 4x</td><td>Thermo Fisher Scientific</td><td>NP0007</td><td></td></tr><tr><td>Odyssey&amp;nbsp;Fc Imager</td><td>LI-COR Biosciences</td><td>43214</td><td></td></tr><tr><td>PageRuler Plus Ladder</td><td>Thermo Fisher Scientific</td><td>26620</td><td></td></tr><tr><td>pGEX6P1 human USP27X</td><td>MRC-PPU Reagents and Services</td><td>DU21193</td><td>https://mrcppureagents.dundee.ac.uk/</td></tr><tr><td>pGEX6P1 human USP27X F313V</td><td>Addgene</td><td>225715</td><td>Koch et at 2024 (PMID: 38182161)</td></tr><tr><td>pGEX6P1 human USP27X S404N</td><td>Addgene</td><td>225717</td><td>Koch et at 2024 (PMID: 38182161)</td></tr><tr><td>pGEX6P1 human USP27X Y381H</td><td>Addgene</td><td>225716</td><td>Koch et at 2024 (PMID: 38182161)</td></tr><tr><td>Pierce Glutathione Agarose</td><td>Thermo Fisher Scientific</td><td>16100</td><td></td></tr><tr><td>PMSF (Phenylmethylsulfonyl fluoride)</td><td>Gold Biotechnology</td><td>P-470-10</td><td></td></tr><tr><td>Polysorbate 20 (Tween 20)</td><td>Fisher Scientific</td><td>AC233360010</td><td></td></tr><tr><td>Rosetta 2 Competent Cells</td><td>Millipore Sigma</td><td>71402-M</td><td></td></tr><tr><td>SimplyBlue SafeStain</td><td>Thermo Fisher Scientific</td><td>LC6060</td><td></td></tr><tr><td>SmartSpec 3000</td><td>Bio-Rad</td><td>170-2501</td><td></td></tr><tr><td>SOC medium</td><td>Thermo Fisher Scientific</td><td>15544034</td><td></td></tr><tr><td>Sodium chloride</td><td>Genesee Scientific</td><td>18-216</td><td></td></tr><tr><td>Sonifier 250</td><td>Branson</td><td>100-132-135</td><td></td></tr><tr><td>Sorvall RC 6 Plus Centrifuge</td><td>Thermo Fisher Scientific</td><td>46910</td><td></td></tr><tr><td>TCEP (Tris-(carboxyethyl) phosphine hydrochloride)</td><td>Gold Biotechnology</td><td>TCEP10</td><td></td></tr><tr><td>Terrific Broth Powder</td><td>Genesee Scientific</td><td>18-225</td><td></td></tr><tr><td>Tris Base</td><td>Genesee Scientific</td><td>18-146</td><td></td></tr><tr><td>XCell SureLock Mini-Cell and XCell II Blot Module&amp;nbsp;</td><td>Thermo Fisher Scientific</td><td>EI0002</td><td></td></tr></tbody></table>

measuring enzymatic activity of neurodevelopmental disorder-associated deubiquitylating enzymes via an in vitro ubiquitin chain cleavage assay

Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay

Neurodevelopmental disorders (NDDs) are associated with impairments in nervous system function but often remain poorly understood at the molecular level. Discrete disorders caused by single genes provide models to investigate mechanisms driving atypical neurodevelopment. Variants of genes encoding deubiquitylating enzyme (DUB) family proteins are associated with several NDDs, but there is a need to determine the pathogenic mechanisms of disorders driven by these gene variants. The impact of gene variants on DUB activity can be experimentally determined using a substrate-independent in vitro ubiquitin cleavage assay. This assay does not require knowledge of downstream substrates to directly measure catalytic activity. Here, the protocol for determining the impact of gene variants on enzymatic activity is modeled using the DUB Ubiquitin Specific Protease 27, X-linked (USP27X), which is mutated in X-linked intellectual disability 105 (XLID105). This experimental pipeline can be used to clarify the mechanisms underlying neurodevelopmental disorders driven by variants in DUB genes.

To determine the impact of XLID105-associated variants on USP27X catalytic activity, GST-tagged wild-type USP27X and the XLID105-associated variant F313V, Y381H, and S404N USP27X proteins were purified from bacteria. These variants are located within the USP catalytic domain of USP27X (Figure 2A). Because USP27X was previously reported to cleave K63 ubiquitin chains31, wild-type USP27X and the XLID105-associated variant F313V, Y381H, and S404N USP27X proteins were incubated with K63-linked di-ubiquitin chains for 1 h. These samples were separated via SDS-PAGE32, and ubiquitin and USP27X proteins were analyzed via immunoblotting. Wild-type USP27X induces di-ubiquitin cleavage, generating mono-ubiquitin (Figure 2B and Supplementary Figure 1). XLID105-associated F313V, Y381H, and S404N USP27X variant proteins did not cleave these chains. Because F313V, Y381H, and S404N variants disrupt USP27X catalytic activity, USP27X functional disruption appears to be the major mechanism underlying XLID1057. Additional quantification and complementary experiments were previously reported7.
<img alt="Ubiquitin protease (USP27X) domain mutations diagram and immunoblot assay for di-Ub analysis." class="xfigimg" src="/files/ftp_upload/67367/67367fig02v2.jpg" data-altupdatedat="1788304762000" data-alt="Figure 2"> 
Figure 2: Impact of XLID105 variants on USP27X deubiquitylating activity. (A) Diagram of the human USP27X protein structure, showing residue numbers and the location of the XLID105 variants evaluated in the USP domain (purple). (B) GST-tagged wild-type USP27X and XLID105 variants (F313V, Y381H, and S404N) were incubated with K63 di-ubiquitin chains for the indicated times. Immunoblot analysis was performed using anti-GST (USP27X) and ubiquitin antibodies. <a href="https://www.jove.com/files/ftp_upload/67367/67367fig02largev2.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
Supplementary Figure 1: Uncropped blots of Figure 2B. <a href="https://www.jove.com/files/ftp_upload/67367/R1%20Koch%202024%20Jove%20supplemental%20Figure.zip" target="_blank">Please click here to download this File.</a>

This protocol explains how to measure the effect of genetic variation associated with neurodevelopmental disorders on deubiquitylating enzyme activity by combining recombinant protein purification with ubiquitin chain cleavage assays.

Neurodevelopmental disorders (NDDs) are associated with impairments in nervous system function but often remain poorly understood at the molecular level. ...

measuring-enzymatic-activity-neurodevelopmental-disorder-associated

Research

JoVE Journal

Biochemistry

The current protocol details a method for measuring the activity of functionally homologous deubiquitinating enzymes. Specialized probes covalently modify the enzyme and allow for detection. This method holds the potential to identify new therapeutic targets.

Method for Measuring the Activity of Deubiquitinating Enzymes in Cell Lines and Tissue Samples

Ubiquitination is a post-translational modification that plays important roles in cellular processes and is tightly coordinated by deubiquitination. Defects in both reactions underlie human pathologies. We provide protocols for conducting ubiquitination and deubiquitination reaction in vitro using purified components.

In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones

This protocol is designed to efficiently quantify ubiquitin-proteasome system (UPS) activity in different cellular compartments of the rodent brain. Users are able to examine UPS functioning in nuclear, cytoplasmic and synaptic fractions in the same animal, reducing the amount of time and number of animals needed to perform these complex analyses.

Quantifying Subcellular Ubiquitin-proteasome Activity in the Rodent Brain

The goal of this manuscript is to present an outline for the comprehensive biochemical and functional studies of the RING-type E3 ubiquitin ligases. This multistep pipeline, with detailed protocols, validates an enzymatic activity of the tested protein and demonstrates how to link the activity to function.

Functional Characterization of RING-Type E3 Ubiquitin Ligases In Vitro and In Planta

This method describes the assessment of global changes in ubiquitin chain topology. The assessment is performed by the application of a mass spectrometry-based targeted proteomics approach.

Ubiquitin Chain Analysis by Parallel Reaction Monitoring

The present study provides detailed in vitro ubiquitylation assay protocols for the analysis of E3 ubiquitin ligase catalytic activity. Recombinant proteins were expressed using prokaryotic systems such as Escherichia coli culture.

In Vitro Analysis of E3 Ubiquitin Ligase Function

A simple and scalable method was developed to assess the functional significance of missense variants in Ube3a, a gene whose loss and gain of function are linked to both Angelman syndrome and autism spectrum disorder.

A Scalable, Cell-Based Method for the Functional Assessment of Ube3a Variants

The experiment used here shows a method of molecular docking combined with probe technologies to predict and validate the interaction between small molecules of traditional Chinese medicine and protein targets.

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

A high-throughput assay for enzyme screening is described. This multiplexed ready-to-use assay kit comprises of pre-chosen Chromogenic Polymer Hydrogel (CPH) substrates and complex Insoluble Chromogenic Biomass (ICB) substrates. Target enzymes are polysaccharide degrading endo-enzymes and proteases.

High-throughput Screening of Carbohydrate-degrading Enzymes Using Novel Insoluble Chromogenic Substrate Assay Kits

Cyclin-dependent kinase 1 (Cdk1) is activated in the G2 phase of the cell cycle and regulates many cellular pathways. Here, we present a protocol for an in vitro kinase assay with Cdk1, which allows the identification of Cdk1-specific phosphorylation sites for establishing cellular targets of this important kinase.

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Learn to measure deubiquitylating enzyme activity for neurodevelopmental disorder research using recombinant protein purification and ubiquitin chain cleavage assays. This substrate-independent method directly assesses genetic variant impacts.

Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay (Video) | JoVE Journal

Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay

Explore More Videos